Lucid Diagnostics (LUCD) Competitors $0.92 -0.05 (-5.15%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends LUCD vs. BDSX, ELMD, NPCE, PROF, BWAY, DRTS, LAKE, GUTS, KRMD, and PDEXShould you be buying Lucid Diagnostics stock or one of its competitors? The main competitors of Lucid Diagnostics include Biodesix (BDSX), Electromed (ELMD), NeuroPace (NPCE), Profound Medical (PROF), BrainsWay (BWAY), Alpha Tau Medical (DRTS), Lakeland Industries (LAKE), Fractyl Health (GUTS), KORU Medical Systems (KRMD), and Pro-Dex (PDEX). Lucid Diagnostics vs. Biodesix Electromed NeuroPace Profound Medical BrainsWay Alpha Tau Medical Lakeland Industries Fractyl Health KORU Medical Systems Pro-Dex Lucid Diagnostics (NASDAQ:LUCD) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations. Which has better earnings and valuation, LUCD or BDSX? Biodesix has higher revenue and earnings than Lucid Diagnostics. Biodesix is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLucid Diagnostics$2.43M20.45-$52.67M-$1.23-0.75Biodesix$49.09M3.84-$52.15M-$0.46-2.83 Does the media prefer LUCD or BDSX? In the previous week, Biodesix had 4 more articles in the media than Lucid Diagnostics. MarketBeat recorded 6 mentions for Biodesix and 2 mentions for Lucid Diagnostics. Biodesix's average media sentiment score of -0.17 beat Lucid Diagnostics' score of -0.25 indicating that Biodesix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lucid Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biodesix 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of LUCD or BDSX? 74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 8.8% of Lucid Diagnostics shares are owned by insiders. Comparatively, 69.2% of Biodesix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend LUCD or BDSX? Lucid Diagnostics presently has a consensus target price of $3.94, indicating a potential upside of 327.76%. Biodesix has a consensus target price of $3.06, indicating a potential upside of 135.38%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Lucid Diagnostics is more favorable than Biodesix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lucid Diagnostics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Biodesix 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor LUCD or BDSX? Lucid Diagnostics received 3 more outperform votes than Biodesix when rated by MarketBeat users. However, 74.36% of users gave Biodesix an outperform vote while only 65.31% of users gave Lucid Diagnostics an outperform vote. CompanyUnderperformOutperformLucid DiagnosticsOutperform Votes3265.31% Underperform Votes1734.69% BiodesixOutperform Votes2974.36% Underperform Votes1025.64% Is LUCD or BDSX more profitable? Biodesix has a net margin of -73.08% compared to Lucid Diagnostics' net margin of -1,227.74%. Lucid Diagnostics' return on equity of 0.00% beat Biodesix's return on equity.Company Net Margins Return on Equity Return on Assets Lucid Diagnostics-1,227.74% N/A -112.67% Biodesix -73.08%-505.95%-44.09% Which has more risk and volatility, LUCD or BDSX? Lucid Diagnostics has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, Biodesix has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. SummaryBiodesix beats Lucid Diagnostics on 10 of the 19 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Lucid Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LUCD vs. The Competition Export to ExcelMetricLucid DiagnosticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.70M$4.45B$5.33B$8.52BDividend YieldN/A41.87%5.07%4.13%P/E Ratio-0.7544.53128.5816.13Price / Sales20.4561.401,490.3793.20Price / CashN/A49.3439.6234.18Price / Book-1.964.264.765.07Net Income-$52.67M$11.52M$118.92M$225.46M7 Day Performance2.46%1.06%0.78%0.54%1 Month Performance8.95%0.92%5.62%3.75%1 Year Performance-28.09%39.37%36.67%29.48% Lucid Diagnostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LUCDLucid Diagnostics2.2298 of 5 stars$0.92-5.2%$3.94+327.8%-29.2%$49.70M$2.43M-0.7570Gap DownBDSXBiodesix3.1246 of 5 stars$1.30-23.5%$3.06+135.4%-6.5%$188.73M$49.09M-2.83220News CoverageHigh Trading VolumeELMDElectromedN/A$22.90-1.5%N/A+118.9%$192.36M$54.72M39.48174NPCENeuroPace3.3184 of 5 stars$6.29-2.5%$14.00+122.6%-8.8%$183.67M$65.42M-5.77170Gap UpPROFProfound Medical2.1805 of 5 stars$7.35+1.1%$13.75+87.1%-13.3%$181.25M$7.20M-6.02150Upcoming EarningsNews CoveragePositive NewsBWAYBrainsWay3.0354 of 5 stars$10.23+2.3%$13.17+28.7%+180.3%$170.64M$31.78M204.64120Gap UpDRTSAlpha Tau Medical2.151 of 5 stars$2.30-1.7%$8.00+247.8%-32.7%$160.24MN/A-5.7580Gap UpLAKELakeland Industries4.8669 of 5 stars$19.27+3.7%$26.50+37.5%+34.7%$142.60M$124.69M80.291,750Analyst DowngradeNews CoverageHigh Trading VolumeGUTSFractyl Health1.6187 of 5 stars$2.84+0.7%$22.00+674.6%N/A$136.11M$119,000.000.00102Gap UpKRMDKORU Medical Systems1.3942 of 5 stars$2.70-7.5%$3.33+23.5%+20.5%$123.80M$28.52M-10.8080Short Interest ↑PDEXPro-Dex1.6513 of 5 stars$36.94+19.1%$30.00-18.8%+108.7%$122.75M$53.84M59.58140News CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies BDSX Alternatives ELMD Alternatives NPCE Alternatives PROF Alternatives BWAY Alternatives DRTS Alternatives LAKE Alternatives GUTS Alternatives KRMD Alternatives PDEX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LUCD) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lucid Diagnostics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lucid Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
